Navigation Links
FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
Date:5/2/2011

. p<0.0001). Patient weight increased in both the TRADJENTA plus pioglitazone and placebo plus pioglitazone groups during the study with an adjusted mean change from baseline of 2.3 kg and 1.2 kg, respectively (p=0.0141).

Adverse reactions reported in greater than or equal to five percent of patients treated with TRADJENTA and more commonly than in patients treated with placebo included nasopharyngitis. Hypoglycemia was more commonly reported in patients treated with the combination of TRADJENTA and sulfonylurea compared with those treated with the combination of placebo and sulfonylurea. The incidence of hypoglycemia was similar to placebo when TRADJENTA was administered as monotherapy or in combination with metformin or pioglitazone. Pancreatitis was reported more often in patients randomized to TRADJENTA (one per 538 person-years versus zero in 433 person-years for comparator).

"Type 2 diabetes is increasing at an alarming rate and we are proud to offer a new treatment option that could potentially help the millions of people with type 2 diabetes whose blood sugar is uncontrolled," said Albert Ros, president and CEO, Boehringer Ingelheim Pharmaceuticals, Inc. "When we introduce a new medicine to the marketplace, our goal is to improve patient care and we are hopeful that TRADJENTA will help do that."

The FDA approval of TRADJENTA marks the first regulatory milestone since the formation of the Boehringer Ingelheim and Eli Lilly and Company worldwide diabetes alliance in January 2011. The alliance leverages the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic.  

"Our alliance with Boehringer Ingelheim represents one of the most robust diabetes pipelines in the pharmaceutical industry," said Enrique Conterno, president of Lilly Diabetes. "TRADJENTA is the first regulatory approval of wh
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... SAN DIEGO , March 27, 2015 /PRNewswire/ ... informatics company, today announced new data showing that, ... Mantis TM technology provided highly equivalent interpretations ... cause disease, and did so in a fraction ... pave the way for more comprehensive genetic analysis ...
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
...  One thousand women in Europe ... identified as a result of the   Sectra OneScreen   ... the risk of painful fractures because inexpensive and effective treatment ... throughout Europe are using this service to screen for osteoporosis, ...
... 2012   ULURU Inc. (NYSE AMEX: ULU),announced today ... been issued by the Therapeutic Goods Administration approving the ... the approval in Australia, Kerry P. Gray, President and ... in the worldwide commercialization of Altrazeal®.  Strategically this is ...
Cached Medicine Technology:1,000th Woman Identified Using Sectra's Analysis Method - European Mammography Clinics Mark Milestone in the Struggle Against Osteoporosis 21,000th Woman Identified Using Sectra's Analysis Method - European Mammography Clinics Mark Milestone in the Struggle Against Osteoporosis 3ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3
(Date:3/27/2015)... While deep learning was the topic of many ... , the CEO of one start-up spoke passionately about using ... well beyond the generally-agreed ceiling of 120 years. , Insilico ... of 12 companies recognized as the hottest GPU-powered startups in ... GTC Emerging Companies Summit have business models focused on ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... Milpitas, CA (PRWEB) March 27, 2015 ... company, today announced it has launched the SM1120 MEMS ... catheter market. The microsensor profile at only 220um ... enabling maneuverability to reach challenging locations. With industry ... per hour, the SM1120 provides a broad operating pressure ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... 2010 Neuralstem, Inc. (NYSE Amex: CUR) announced ... rat brains affected by stroke and differentiated predominantly ... in some motor skill and strength measurements. The ... Stem Cells To Reverse Motor Deficits in Chronic ...
... Families from rural Mexico who receive health care from centralized ... percent less in out-of-pocket expenses and utilize preventive services more ... states, according to a study by researchers at the UCLA ... published in the September issue of the Journal of ...
... By Serena Gordon HealthDay Reporter , MONDAY, Sept. 13 ... rather than the hospital results in higher quality-of-life scores at the ... as well. , A study published online Sept. 13 in ... people who died in intensive care units (ICU) or other areas ...
... small, seemingly benign holes in a child,s heart may ... could be lurking out of sight. These are the ... at Nationwide Children,s Hospital and the Ohio State University ... form of congenital heart disease, ventricular septal defect. The ...
... CLEMENTE, Calif. (September 13, 2010) USGI Medical, ... updated multi-center results confirm durability of the company,s ... more in a variety of incisionless gastrointestinal (GI) ... of Surgery, Endolumenal) to repair dilated tissue after ...
... used to treat attention-deficit/hyperactivity disorder (ADHD) also provides ... that affect many childhood cancer survivors, according to ... Research Hospital investigators. Researchers reported that one ... survivors scored better on tests of sustained attention ...
Cached Medicine News:Health News:Neuralstem stem cells survive and differentiate into neurons in rats with stroke 2Health News:Centralized health care more cost-effective, offers better access to preventive services 2Health News:Centralized health care more cost-effective, offers better access to preventive services 3Health News:Dying at Home Often Easier on Cancer Patients, Caregivers 2Health News:Dying at Home Often Easier on Cancer Patients, Caregivers 3Health News:Study identifies underlying dysfunction of seemingly non-critical heart condition 2Health News:USGI medical tissue anchors show durability beyond 1 year 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 3
... digital single plane C-arm angiography system is ... performance and an expansive range of diagnostic ... to ECG triggered. ... of the art dynamic Flat Detector technology, ...
... Meta-4 Computerized ENG utilizes a ... comprehensive nystagmus and ocular motor ... storage, data analysis and reanalysis ... data in the Meta-4 software ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: